Oncotelic Therapeutics (OTLC) Gains (Losses) on Sale of Assets & Investments (2026)
Oncotelic Therapeutics (OTLC) reported Non Operating Investment Income of $300,000 for Q2 2026.
Powered by 
Analysis
Oncotelic Therapeutics (OTLC) Gains (Losses) on Sale of Assets & Investments (2026) Analysis & Trends
For FY2025, Oncotelic Therapeutics posted Non Operating Investment Income of $365.35 million.
- By year, Non Operating Investment Income came in at $12,706 in FY2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gains on Sales (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,248.16 Bn | 1,221.78 Bn | 20.46 Bn | - |
| 2 | Johnson & Johnson | 670.28 Bn | 590.14 Bn | 17.30 Bn | - |
| 3 | AbbVie | 514.81 Bn | 482.82 Bn | 13.12 Bn | - |
| 4 | Merck | 363.68 Bn | 326.63 Bn | 13.19 Bn | - |
| 5 | Novartis Ag | 314.66 Bn | 287.90 Bn | - | - |
| 6 | Astrazeneca | 292.36 Bn | 266.25 Bn | 13.26 Bn | - |
| 7 | Amgen | 248.52 Bn | 200.18 Bn | 7.58 Bn | - |
| 8 | Gilead Sciences | 209.74 Bn | 184.85 Bn | 6.73 Bn | - |
| 9 | Pfizer | 165.67 Bn | 113.03 Bn | 12.56 Bn | - |
| 10 | Oncotelic Therapeutics | 6.40 Mn | 5.57 Mn | - | 300,000.00 |
API Access
Oncotelic Therapeutics Gains (Losses) on Sale of Assets & Investments API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=non-operating-investment-income&ticker=OTLC&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "non-operating-investment-income", "ticker": "OTLC", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=non-operating-investment-income&ticker=OTLC&period=max&api_key=YOUR_API_KEY");
const data = await res.json();